METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC HER2-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HER2-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HER2-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test could help doctors switch cancer drugs faster
Disease control Recruiting nowThis phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earl…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New trial aims to outsmart cancer by adjusting chemo doses in real time
Disease control Recruiting nowThis phase 2 trial tests whether giving the chemotherapy drug capecitabine in a flexible, response-based way (adaptive therapy) can better control metastatic ER-positive breast cancer. About 35 adults with advanced, hormone-resistant disease will receive doses that are adjusted b…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New vaccine aims to boost immune system against advanced breast cancer
Disease control Recruiting nowThis study tests a vaccine called STEMVAC in people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to help the immune system attack cancer cells. Participants will receive STEMVAC along with their usual hormone therapy, a targ…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 03:00 UTC
-
Can a PET scan predict which breast cancer patients will respond to treatment?
Knowledge-focused Recruiting nowThis study tests whether a special type of PET scan (FFNP-PET/CT) can predict how well a drug combination (abemaciclib plus hormone therapy) works in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants with metastatic or locally adva…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC